Acute statin treatment in reducing risk after acute coronary syndrome: The MIRACL (Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering) trial

Current Opinion in Cardiology

Volumn 16, Issue 6, 2001, Pages 390-393

  Ahsan, Chowdhury H ^a   Shah, Arti ^a   Ezekowitz, Michael ^a  

^a HAHNEMANN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; INTERCELLULAR ADHESION MOLECULE 1; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; STATIN; TISSUE INHIBITOR OF METALLOPROTEINASE; VASCULAR CELL ADHESION MOLECULE 1;

ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; DRUG EFFECT; EXTRACELLULAR MATRIX; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; SMOOTH MUSCLE FIBER; ST SEGMENT ELEVATION;

ANGINA, UNSTABLE; ANTICHOLESTEREMIC AGENTS; DOUBLE-BLIND METHOD; HEALTH BEHAVIOR; HEART CONDUCTION SYSTEM; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MYOCARDIAL INFARCTION; PRIMARY PREVENTION; PROSPECTIVE STUDIES; PYRROLES; TREATMENT OUTCOME;

EID: 0035215024     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-200111000-00013     Document Type: Review

References (22)

1. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
2. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
4. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q wave myocardial infarction
5. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study
6. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making
7. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month
8. Effects of short-term treatment of hyperlipidemia on coronary vasodilator function and myocardial perfusion in regions having substantial impairment of baseline dilator reserve
9. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: The RECIFE (Reduction of Cholesterol in Ischemia and Function of Endothelium) trial
10. Hyperlipidemia and coronary disease: Correction of the increased thrombogenic potential with cholesterol reduction
11. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: A randomized controlled trial
12. Atherosclerosis-an inflammatory disease
13. Mechanisms of modifying atherosclerotic disease-from lipids to vascular biology
14. Plaque stabilization: The role of lipid lowering
15. Relationship between plasma LDL concentration and recurrent coronary events in the cholesterol and recurrent coronary events trial
16. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
17. Primary prevention of acute coronary events with Lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS study
18. Lipid lowering improves endothelial dysfunctions
19. Effect of lovastatin on intimal hyperplasia after balloon angioplasty: A study in an atherosclerotic hypercholesterolemic rabbit
20. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases and cell death in human carotid plaques: Implication for plaque stabilization
21. Early statin treatment following acute myocardial infarction and 1-year survival
22. Clinical relevance of statins: Instituting treatment early in acute coronary syndrome patients